RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Ramucirumab Improves Survival in Stage IV NSCLC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 14
SP 14
OP 14
DO 10.1177/155989771414006
UL http://mdc.sagepub.com/content/14/14/14.abstract
AB Ramucirumab (IMC-1121B) is a human immunoglobulin G1 monoclonal antibody that targets the extracellular domain of vascular endothelial growth factor receptor 2. A Study of Chemotherapy and Ramucirumab versus Chemotherapy Alone in Second Line Non—Small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy [REVEL; NCT01168973; Garon EB et al. Lancet 2014] showed that ramucirumab combined with docetaxel extended survival in patients with advanced non—small cell lung cancer (NSCLC) compared with placebo plus docetaxel.